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The paper by Jones-Lo ´pez et al. in this
week’s PLoS Medicine [1] (hereinafter ‘‘the
Uganda study’’) illustrates the challenge of
conducting research in resource-con-
strained settings. At the time the study
was proposed and initiated, the prevalence
of multidrug resistant tuberculosis (MDR-
TB) in Uganda was unknown. Further,
second-line therapy for MDR-TB, avail-
able in other settings, was not available in
the country. The Uganda study accord-
ingly highlights at least two classic ethical
conundrums: (1) should research be con-
ducted in a setting if the existing standard
of care for the health issue under investi-
gation is ‘‘no treatment,’’ despite effica-
cious treatment existing elsewhere? and (2)
should investigators introduce an effica-
cious standard of care in a setting if it
would not otherwise be available?
Is the Uganda Study Ethically
Defensible? The Stance of
Research Ethics Guidelines
It is worthwhile examining the ethics of
the Uganda study through the lens of pro-
minent international research ethics guide-
lines. Although these instruments are not
binding on any setting, including Uganda,
they offer helpful guidance on a range of
issues that confront researchers. According
to the Council for International Organiza-
tions of Medical Sciences (CIOMS) Guide-
lines (formally known as International
EthicalGuidelinesforBiomedicalResearch
Involving Human Subjects; hereinafter
‘‘CIOMS Guideline’’) [2]:
‘‘Sponsorsofresearch orinvestigators
cannot, in general, be held account-
able for unjust conditions where the
research is conducted, but they must
refrain from practices that are likely
to worsen unjust conditions or con-
tribute to new inequities…In general,
the research project should leave low-
resource countries or communities
better off than previously or, at least,
no worse off.’’
On the issue of conducting research in
populations and communities with limited
resources, Guideline 10 of the CIOMS
Guideline states that
‘‘before undertaking research in a
population or community with lim-
ited resources, the sponsor and the
investigator must make every effort
to ensure that:
N the research is responsive to the health
needs and the priorities of the popula-
tion or community in which it is to be
carried out; and
N any intervention or product developed,
or knowledge generated, will be made
reasonably available for the benefit of
that population or community.’’
Guideline 10’s accompanying commen-
tary states:
‘‘It is not sufficient simply to deter-
mine that a disease is prevalent in
the population and that new or
further research is needed: the
ethical requirement of ‘responsive-
ness’ can be fulfilled only if success-
ful interventions or other kinds of
health benefit are made available to
the population. This is applicable
especially to research conducted in
countries where governments lack
the resources to make such products
or benefits widely available.’’
Paragraph 19 of the 2000 version of the
Declaration of Helsinki [3]—which was
applicable at the time the Uganda study
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Linked Research Article
Jones-Lo ´pez EC, Ayakaka I, Levin J,
Reilly N, Mumbowa F, et al. (2011)
Effectiveness of the Standard WHO
Recommended Retreatment Regi-
men (Category II) for Tuberculosis
in Kampala, Uganda: A Prospective
Cohort Study. PLoS Med 8: e427.
doi:10.1371/journal.pmed.1000427
Prospective evaluation of the effec-
tiveness of the WHO-recommended
standardized retreatment regimen
for tuberculosis by Edward Jones-
Lo ´pez and colleagues reveals an
unacceptable proportion of unsuc-
cessful outcomes.
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research is only justified if there is a
reasonable likelihood that the populations
in which the research is carried out stand
to benefit from the results of the research.’’
Paragraph 30 of the 2000 version of the
Declaration of Helsinki further states: ‘‘At
the conclusion of the study, every patient
entered into the study should be assured of
access to the best proven prophylactic,
diagnostic and therapeutic methods iden-
tified by the study.’’
Paragraph 30’s accompanying note of
clarification, which was added by the
World Medical Association General As-
sembly in 2004 [4], states:
‘‘The WMA hereby reaffirms its
position that it is necessary during
the study planning process to iden-
tify post-trial access by study partic-
ipants to prophylactic, diagnostic
and therapeutic procedures identi-
fied as beneficial in the study or
access to other appropriate care.
Post-trial access arrangements or
other care must be described in the
study protocol so the ethical review
committee may consider such ar-
rangements during its review.’’
Paragraph 7 of the 2008 version of the
Declaration of Helsinki [5]—which be-
came applicable before the Uganda study
ended—states:
‘‘Medical research involving a dis-
advantaged or vulnerable popula-
tion or community is only justified if
the research is responsive to the
health needs and priorities of this
population or community and if
there is a reasonable likelihood that
this population or community stands
to benefit from the results of the
research.’’
Given the above, it could be argued that
the Uganda study was unethical if the
following conditions were met:
1. The investigators initiated the study in
a setting where drug-resistant TB was
likely prevalent, and second-line TB
therapy was not available in that
setting’s public sector; and
2. Notwithstanding the factors outlined in
point 1, the investigators made no
reasonable efforts to change this state
of affairs (i.e., they left participants who
required second-line therapy untreated
for the entire duration of the study).
As MDR-TB was almost certainly
prevalent in Uganda at the study’s
commencement, the Uganda study was
clearly responsive to the health needs of
the study setting. Moreover, the investi-
gators made a praiseworthy good-faith
attempt to initiate a second-line treatment
program in Uganda, when none existed
previously. To this end, they provided
second-line treatment regimens to a
cohort of study participants diagnosed
with MDR-TB, before the study conclud-
ed. While it may be argued that the
investigators could have treated more
participants infected with MDR-TB with
second-line drugs earlier (seven study
participants with MDR-TB accessed sec-
ond-line treatment later in the study
through a pilot treatment program initi-
ated by the investigators), the study is
ethically defensible, if one considers that
several logistic issues have to be addressed
before a treatment program can be
initiated.
For example, securing funding, ob-
taining preferentially priced second-line
TB drugs, training health personnel in
MDR-TB treatment, developing a di-
rectly observed therapy (DOT)-Plus pro-
gram, developing laboratory capacity for
drug-susceptibility testing, and establish-
ing hospital infection control measures,
are time-consuming activities and could
have prevented earlier second-line ther-
apy initiation in the study setting.
Further, the Uganda study findings will,
on a balance of probability, likely
achieve its goal: inspire MDR-TB treat-
ment policy reform in Uganda (and
other similar settings), thereby satisfying
the requirement that the local popula-
tion benefit from the results of the
research.
Lessons for Others
The Uganda study holds valuable
lessons for others contemplating conduct-
ing research in resource-scarce settings.
While not conducting a study in a setting
where no efficacious standard of care
exists may, at face value and in certain
instances, seem a more ethically defensible
option, it could overall have more negative
consequences. For instance, crucial epide-
miological evidence that could demon-
strate the actual state of disease prevalence
in a setting, and which may be pivotal to
compelling (or shaming) apathetic, obsti-
nate, and indifferent governments to
change their existing treatment policy,
may end up never being yielded. Accord-
ingly, the relevant health crisis will remain
unaddressed, resulting in dire public
health consequences for that setting, and
in some instances, the surrounding region.
The Uganda study investigators were thus
justifiable in conducting the study in
Uganda.
Further, as was the case in the Uganda
study, the investigators’ role should not
be limited to merely highlighting a
problem. The duty of beneficence re-
quires investigators to assume an advo-
cacy role. This includes making reason-
able attempts to change the prevailing
state of affairs (i.e., the absence of
efficacious treatment in the country). To
this end, investigators could follow the
example of the Uganda study and
provide the efficacious standard of care
to study participants as soon as practical-
ly possible for the duration of the study
(and, if necessary, a limited period
thereafter). Moreover, they could attempt
to secure an undertaking from the
authorities that the state will assume the
responsibility of continuing that standard
of care in the study setting, post-trial, and
eventually expanding its access through-
out its territorial jurisdiction. Admittedly,
investigators do not have the power to
compel authorities to approve their study,
to assume post-trial responsibilities, or to
implement an efficacious standard of care
beyond the study site. However, this
should not stop investigators from trying
to do so.
Conclusion
The Uganda study has undoubtedly
addressed an important knowledge gap
in science. It will hopefully herald revisions
to Uganda’s TB treatment program and
inspire similar reforms elsewhere. Equally
significant, the study catalyzed the provi-
sion of second-line TB therapy in that
country. In so doing, the study has
undoubtedly left the local population
better off compared to before its com-
mencement. These two factors, alone,
make the Uganda study ethically defensi-
ble.
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